DCT

1:26-cv-00039

Ingenus Pharma LLC v. Mylan Pharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00039, N.D. W. Va., 04/10/2026
  • Venue Allegations: Venue is alleged to be proper because Defendant is a West Virginia corporation with its principal place of business in the district, is subject to personal jurisdiction, and has previously consented to venue in the district in other patent litigation.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's Cyclophosphamide Injection constitutes an act of patent infringement.
  • Technical Context: The dispute centers on pharmaceutical formulations designed to create a stable, ready-to-use liquid version of the chemotherapy drug cyclophosphamide, which is historically unstable in solution.
  • Key Procedural History: The complaint notes that U.S. Patent No. 10,993,952 was previously found invalid as indefinite under 35 U.S.C. §112 by the U.S. District Court for the Northern District of Illinois in separate litigation. That decision is currently on appeal to the U.S. Court of Appeals for the Federal Circuit. Plaintiff states it is "provisionally" asserting the '952 patent in this action pending a potential reversal on appeal.

Case Timeline

Date Event
2015-02-16 Priority Date for '952 and '767 Patents
2020-07-30 Plaintiff's NDA No. 212501 for Cyclophosphamide Injection Approved
2021-05-04 U.S. Patent No. 10,993,952 Issued
2021-11-19 Plaintiff's Supplemental NDA Approved
2025-02-19 Date of Mylan's Notice Letter regarding ANDA submission
2025-05-09 N.D. Illinois court rules '952 patent claims invalid in separate litigation
2025-06-17 U.S. Patent No. 12,329,767 Issued
2026-04-10 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,993,952 - "Stable Ready to Use Cyclophosphamide Liquid Formulations"

The Invention Explained

  • Problem Addressed: The patent describes the active pharmaceutical ingredient cyclophosphamide as being "susceptible to hydrolysis," making it unstable in liquid solutions ʼ952 Patent, col. 2:36-38 Traditionally, this required the drug to be supplied as a lyophilized (freeze-dried) powder that must be reconstituted with a diluent before administration, a process which "decreases the ease of administration" ʼ952 Patent, col. 2:60-62
  • The Patented Solution: The invention is a "ready to use" liquid formulation that does not require reconstitution ʼ952 Patent, col. 2:32-35 The solution uses a specific solvent system, comprising ethanol, polyethylene glycol, and propylene glycol, along with an antioxidant, to dissolve the cyclophosphamide and maintain its chemical stability over time, thereby avoiding the need for lyophilization ʼ952 Patent, abstract '952 Patent, col. 3:24-30
  • Technical Importance: The technology aims to provide a more convenient and potentially safer formulation for a widely used chemotherapy drug by eliminating the on-site reconstitution step.

Key Claims at a Glance

The complaint does not identify specific asserted claims, alleging infringement of "one or more claims" Compl. ¶40 Independent claim 1 is representative:

  • A stable liquid parenteral formulation of cyclophosphamide comprising:
  • cyclophosphamide in a concentration of about 12% to about 23% by weight;
  • ethanol content of about 70% to about 75% by weight;
  • both polyethylene glycol and propylene glycol, with a specific mass ratio between approximately 1.0:1.0 and 2.0:1.0;
  • about 3.4% to about 8.8% polyethylene glycol by weight;
  • about 3.4% to about 4.4% propylene glycol by weight; and
  • a stability requirement wherein decomposition into specific, named impurities is less than 0.5% after 7 days of storage under accelerated conditions (40° C./75% RH).

U.S. Patent No. 12,329,767 - "Stable Ready to Use Cyclophosphamide Liquid Formulations"

The Invention Explained

  • Problem Addressed: The ʼ767 patent, a continuation of the application leading to the ʼ952 patent, addresses the same technical problem of cyclophosphamide's instability in liquid solutions ʼ767 Patent, col. 2:50-53
  • The Patented Solution: The patented solution is functionally identical to that of the ʼ952 patent: a stable, ready-to-use liquid formulation using a specific solvent and antioxidant system to prevent degradation ʼ767 Patent, abstract '767 Patent, col. 4:15-22
  • Technical Importance: As with the parent patent, the technology's contribution is a more convenient formulation of a chemotherapy drug that avoids manual reconstitution.

Key Claims at a Glance

The complaint does not identify specific asserted claims, alleging infringement of "one or more claims" Compl. ¶50 Independent claim 1 is representative and is compositionally similar to claim 1 of the '952 patent, but with slightly different quantitative ranges:

  • A stable liquid parenteral formulation of cyclophosphamide comprising:
  • cyclophosphamide in a concentration of 10.72% to 22.62% by weight;
  • ethanol content of 70.26% to 75.88% by weight;
  • both polyethylene glycol (3.38% to 8.90%) and propylene glycol (3.38% to 4.50%), with a mass ratio between approximately 1.0:1.0 and 2.0:1.0;
  • less than 3% of an antioxidant by weight;
  • optionally other adjuvants; and
  • a stability requirement wherein decomposition into specific, named impurities is less than 0.5% after 7 days of storage under accelerated conditions.

III. The Accused Instrumentality

Product Identification

  • Defendant's proposed generic cyclophosphamide solution for intravenous injection, which is the subject of Abbreviated New Drug Application (ANDA) No. 220273 Compl. ¶9

Functionality and Market Context

  • The complaint alleges that the accused product is a generic version of Plaintiff's own FDA-approved Cyclophosphamide Injection (NDA No. 212501) and will have the same indication for the treatment of malignant diseases Compl. ¶19 Compl. ¶33 The complaint does not provide any technical details regarding the specific formulation or composition of Defendant's ANDA product. The alleged act of infringement is the submission of the ANDA itself, which seeks FDA approval to market the generic product before the expiration of the patents-in-suit Compl. ¶39 Compl. ¶49

IV. Analysis of Infringement Allegations

The complaint does not contain a claim chart or provide a detailed, element-by-element analysis of how the accused ANDA product infringes the patents-in-suit. The infringement allegation is statutory, based on 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA seeking approval to market a generic drug before patent expiration as an act of infringement Compl. ¶39 Compl. ¶49 Plaintiff alleges that upon approval, the commercial manufacture, use, or sale of the ANDA product will infringe one or more claims of the '952 and '767 patents Compl. ¶40 Compl. ¶50 Because the specific formulation of the accused product is detailed within the confidential ANDA and not public, a more detailed analysis is not possible based on the complaint alone.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • The Term: "about"

    • Context and Importance: This term modifies all the concentration and percentage ranges in the independent claims of both patents. The scope of "about" will be critical in determining whether Defendant's formulation, if its component percentages fall near but not exactly within the recited numerical ranges, still infringes.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The repeated use of "about" and "approximately" in the claims suggests the patentee did not intend for the ranges to be interpreted as strict, absolute endpoints '952 Patent, cl. 1 '767 Patent, cl. 1
      • Evidence for a Narrower Interpretation: The patents provide examples with specific, precise quantities for each component (e.g., '952 Patent, Table 1; '952 Patent, Example 1). A party could argue these precise examples inform the meaning of "about" and limit it to a very narrow degree of variance.

  • The Term: "stable"

    • Context and Importance: This term appears in the preamble of the independent claims (e.g., "A stable liquid parenteral formulation"). Practitioners may focus on this term because its definition could determine whether the claim is limited by the specific stability test described later in the claim.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A party might argue that "stable" should be given its ordinary meaning in the pharmaceutical arts, which could encompass stability characteristics beyond those measured in the specific test recited in the claim.
      • Evidence for a Narrower Interpretation: The "wherein" clause of the claims provides a highly specific, objective definition of stability: "wherein, after storage for 7 days at 40° C./75% RH, decomposition to form any of the following impurities is less than 0.5%" '952 Patent, cl. 1 A party will likely argue that the patentee acted as its own lexicographer, defining "stable" for the purposes of the patent exclusively by this quantitative test, precluding any broader interpretation.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Defendant will actively induce infringement by encouraging acts of direct infringement with knowledge of the patents Compl. ¶42 Compl. ¶52 It also pleads contributory infringement, alleging the ANDA product is "especially made or especially adapted for a use that infringes" and has "no substantial noninfringing uses" Compl. ¶43 Compl. ¶53
  • Willful Infringement: The complaint alleges Defendant had "actual and constructive notice" of the patents prior to filing its ANDA and lacked a "reasonable basis for asserting that the commercial manufacture, use, offer for sale, or sale of the ANDA Product will not infringe" Compl. ¶44 Compl. ¶54 The complaint further alleges that Defendant's conduct renders the case "exceptional" and entitles Plaintiff to attorneys' fees under 35 U.S.C. § 285 Compl. ¶45 Compl. ¶55

VII. Analyst's Conclusion: Key Questions for the Case

  • A threshold issue is one of patent viability: will the Federal Circuit affirm or reverse the Northern District of Illinois's judgment that the claims of the '952 patent are invalid for indefiniteness? The outcome of that appeal will be highly consequential for the infringement count related to the '952 patent.
  • The central technical dispute will be one of compositional identity: does the confidential formulation disclosed in Defendant's ANDA contain the exact components in the specific concentrations, percentages, and ratios required by the asserted claims of the '767 patent (and the '952 patent, if it survives appeal)?
  • A key legal question will be one of definitional scope: how broadly will the court construe the term "about"? The infringement analysis may hinge on whether the court adopts a narrow interpretation tied to the patent's examples or a more flexible one, which could capture formulations that fall just outside the explicitly recited numerical ranges.
Loading Complaint